Results 1 to 10 of about 33,038 (222)

Diethylstilbestrol in castration‐resistant prostate cancer [PDF]

BJU International, 2012
Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Diethylstilbestrol (DES) was the first hormone treatment used for prostate cancer and has also ...
Wilkins, A, Shahidi, M, Parker, C, Gunapala, R, Thomas, K, Huddart, R, Horwich, A, Dearnaley, D   +7 more
openaire   +6 more sources

Ceramide Regulates Anti-Tumor Mechanisms of Erianin in Androgen-Sensitive and Castration-Resistant Prostate Cancers

Frontiers in Oncology, 2021
Prostate cancer is the second most prevalent malignancy worldwide. In the early stages, the development of prostate cancer is dependent on androgens. Over time with androgen deprivation therapy, 20% of prostate cancers progress to a castration-resistant ...
I Gusti Md Gde Surya C. Trapika, I Gusti Md Gde Surya C. Trapika, Xin Tracy Liu, Long Hoa Chung, Felcia Lai, Felcia Lai, Chanlu Xie, Chanlu Xie, Yang Zhao, Shaohui Cui, Jinbiao Chen, Collin Tran, Qian Wang, Shubiao Zhang, Anthony S. Don, Anthony S. Don, George Qian Li, Jane R. Hanrahan, Yanfei Qi   +18 more
doaj   +1 more source

Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade

BMC Urology, 2023
Background Although the second-generation androgen receptor inhibitors and taxanes have recently been recommended for the initial treatment of metastatic prostate cancer, bicalutamide and flutamide are still used in a large number of cases. Therefore, it
Daisuke Obinata, Sho Hashimoto, Hideaki Uchida, Ken Nakahara, Tsuyoshi Yoshizawa, Junichi Mochida, Kenya Yamaguchi, Satoru Takahashi   +7 more
doaj   +1 more source

Identification of the α2 chain of interleukin‐13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient‐derived xenograft models

Cancer Reports, 2023
Background Several treatment strategies use upfront chemotherapy or androgen receptor axis‐targeting therapies for metastatic prostate cancer. However, there are no useful biomarkers for selecting appropriate patients who urgently require these ...
Takahiro Nagai, Naoki Terada, Masato Fujii, Yasuhisa Nagata, Kozue Nakahara, Shoichiro Mukai, Kosuke Okasho, Yuki Kamiyama, Shusuke Akamatsu, Takashi Kobayashi, Kei Iida, Masatsugu Denawa, Masatoshi Hagiwara, Takahiro Inoue, Osamu Ogawa, Toshiyuki Kamoto   +15 more
doaj   +1 more source

Dynamic Profiling of Exosomal microRNAs in Blood Plasma of Patients with Castration-Resistant Prostate Cancer

Frontiers in Bioscience-Scholar, 2022
Prostate cancer is one of the most common and socially significant cancers among men. The aim of this study was to identify significant changes in the expression of exosomal miRNAs associated with an increase in the level of prostate specific antigen in ...
Elena A. Pudova, Anastasiya A. Kobelyatskaya, Irina V. Katunina, Anastasiya V. Snezhkina, Maria S. Fedorova, Zulfiya G. Guvatova, Kirill M. Nyushko, Boris Y. Alekseev, Vladislav S. Pavlov, Maria V. Savvateeva, Alexander A. Kudryavtsev, George S. Krasnov, Anna V. Kudryavtseva   +12 more
doaj   +1 more source

Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer

IJU Case Reports, 2022
Introduction Prostate cancer with a microsatellite instability‐high or mismatch repair‐deficient status is not common. Few reports of the response to pembrolizumab in metastatic castration‐resistant prostate cancer in a real‐world setting have been ...
Takumi Kageyama, Norihito Soga, Sho Sekito, Seiichi Kato, Yuji Ogura, Takahiro Kojima, Masahiro Kanai, Takahiro Inoue   +7 more
doaj   +1 more source

A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer

Frontiers in Oncology, 2023
Prostate cancer is the most common cancer in men. About 6% of those diagnosed will develop metastatic disease. Unfortunately, metastatic prostate cancer is fatal. Prostate cancer can be castration sensitive or castration resistant.
Diana V. Maslov, Quinne Sember, Jason Cham, Munveer Bhangoo   +3 more
doaj   +1 more source

A case of repeat oligoprogressive castration‐resistant prostate cancer treated with pulmonary metastasectomy

IJU Case Reports, 2023
Introduction Several retrospective studies have demonstrated the efficacy of progressive site‐directed therapy for oligoprogressive castration‐resistant prostate cancer.
Takahiko Soma, Soichiro Yoshida, Ryo Wakejima, Towako Taguchi, Shohei Fukuda, Hajime Tanaka, Minato Yokoyama, Kenichi Ohashi, Kenichi Okubo, Yasuhisa Fujii   +9 more
doaj   +1 more source

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer

IJU Case Reports, 2023
Introduction Transient decrease in serum prostate‐specific antigen level can occur after abiraterone acetate withdrawal in male patient with metastatic castration‐resistant prostate cancer.
Masaru Tani, Yujiro Hayashi, Airi Miki, Teppei Wakita, Yuki Horibe, Yoichi Kakuta, Koichi Tsutahara, Tetsuya Takao   +7 more
doaj   +1 more source

Nonmetastatic Castration-Resistant Prostate Cancer [PDF]

Korean Journal of Urology, 2014
After the introduction of prostate cancer screening with the prostate-specific antigen (PSA) test, we have witnessed a dramatic stage migration. As a result, an increasing number of patients are diagnosed at earlier stages and receive local treatments including surgery or radiation.
Hong, Jun Hyuk, Kim, Isaac Y.
openaire   +2 more sources